Year: 2022

– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast Today at 8:30 a.m. ET – NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) —  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a business update and reported its financial results for the quarter ended September 30, 2022. “As announced this morning, we look forward to executing on our revised protocol and statistical analysis plan (SAP) for the Phase 3 registrational REGAL study of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) as well as evaluating the next steps for our ovarian cancer program for GPS in combination with PD1 inhibitors following...

Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) —  Sema4 Holdings Corp. (Nasdaq: SMFR) (“Sema4”), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity to generate more complete understanding of complex diseases and how to treat them, fueled by its industry-leading genomic and data platforms. As a result,...

ATHENS, Greece, Nov. 14, 2022 (GLOBE NEWSWIRE) — Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today its results for the three and nine-month periods ended September 30, 2022. Third Quarter 2022 Financial Highlights:Total net revenues of $46.0 million. Net income and net income attributable to common shareholders of $25.2 million or $3.50 earnings per share basic and diluted. Adjusted net income attributable to common shareholders1 for the period was $20.9 million or $2.90 per share basic and diluted.Adjusted EBITDA1 was $26.2 million.An average of 18.0 vessels were owned and operated during the third quarter of 2022 earning an average time charter equivalent rate of $30,893 per day.Declared...

Sales in million US$ – 2021 and 2022 Sales in million US$ – 2021 and 2022MONTREAL, Nov. 14, 2022 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (Dynacor or the Corporation) released its unaudited condensed interim consolidated financial statements and the management’s discussion and analysis (MD&A) for the third quarter ended September 30, 2022. These documents have been filed electronically with SEDAR at www.sedar.com and will be available on the Corporation’s website www.dynacor.com. (All figures in this press release are in Ms of US$ unless stated otherwise. All amounts per share are in US$. All variance % are calculated from rounded figures. Some additions might be incorrect due to rounding). Q3-2022 OVERVIEW AND HIGHLIGHTS OVERVIEW Dynacor completed the three-month period ended September...

Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer Center (IMMUNOCERV) and The National Cancer Institute at SITC 2022 Announced successful end-of-Phase 2 meeting with FDA for VERSATILE-002, allowing preparation for a registrational trial  Company to host conference call and webcast today at 8:00 AM ESTFLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, will discuss its financial results for the quarter ended September 30, 2022 and provide a business update on its conference call today. Recent Business Highlights:PDS0101 Lead Drug CandidateVERSATILE-002 Phase 2 Clinical...

Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash runway into 3Q 2024 NEW YORK and CLEVELAND, Nov. 14, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced financial results for the third quarter of 2022. “The positive topline data from the Phase 3 VIITAL study provides strong support for EB-101’s potential and validation of the Abeona team’s extensive efforts,” said Vish Seshadri, Chief Executive Officer of Abeona. “This is an exciting time for Abeona as we are sharply focused on submitting a Biologics License Application for EB-101 to the U.S. FDA. With the additional capital raised after quarter-end, we are now well-funded into the third quarter of 2024,...

Completed RE104 Phase 1 prespecified dose cohorts and on track to deliver interim Phase 1 analysis in the first calendar quarter of 2023. Appointed Greg Mayes as President and Chief Executive Officer, with Joseph del Moral moving into the role of Chairman. Announced reinforcement of the executive leadership team with the addition of highly experienced pharmaceutical professionals: Edward Smith as Chief Financial Officer, Dr. Aviva Asnis-Alibozek as Vice President, Medical Affairs, and Curtis Weber as General Counsel. At September 30, 2022, the Company held cash, cash equivalents and short-term investments of $36.7 million Canadian dollars.TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions...

WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2022 and provided key business updates. “The Company had several notable deliverables this quarter and continues to focus on progressing its planned development of istaroxime. The positive results of the SEISMiC study of istaroxime in early cardiogenic shock have been well received in many scientific forums. At the same time, our team has been active in working to advance istaroxime into the next clinical trial in early cardiogenic shock. To support development and company operations, we are addressing our resources by exploring options for financing, as...